Mitra RxDx Announces $40 Million Financing Round

Date : 07/11/2018 @ 8:00PM
Source : PR Newswire (US)

Mitra RxDx Announces $40 Million Financing Round

BOSTON, July 11, 2018 /PRNewswire/ -- Mitra RxDx (dba Mitra Biotech), a privately held biotech company and global leader in advancing truly personalized oncology treatment, announced today the completion of a $40 million financing round. The round was led by Northpond Ventures, headquartered in Bethesda, Maryland. Existing investors Accel, Sequoia Capital, Sands Capital Ventures, and RA Capital Management also participated. Cumulative funding to date now totals $76 million.

Mitra's CANscript™ platform delivers powerful, individualized treatment response predictions — with exceptionally high correlation to clinical outcomes — to inform patient-specific cancer treatment selection and support more effective and efficient cancer drug development.

"Northpond is excited to join Mitra, as the CANscript platform has the potential to meaningfully improve how we treat cancer patients," said Michael P. Rubin, M.D., Ph.D., Founder and CEO at Northpond. "We are proud to begin working with the current investors to help Mitra accomplish their clinical and commercial goals." Michael will join existing investor representatives from Accel, Sequoia, Sands, and Tata Capital Innovation Fund on the Mitra board.

"These funds will allow us to expand our commercial efforts, while also continuing to build the clinical evidence necessary to accelerate adoption and secure reimbursement in the U.S. and other key markets," said Mallikarjun Sundaram, President, Co-Founder, and CEO of Mitra. "We enthusiastically welcome Northpond, and greatly appreciate the continued support from our current investors."

About Mitra:
Founded in 2010, Mitra is headquartered in Greater Boston and maintains a significant research and laboratory presence in Bengaluru, India.

The company is led by an accomplished and deeply experienced team of researchers, scientists, and medical commercialization professionals.

To learn more about Mitra, CANscript, or the recent investment round, please contact:

Parker Cassidy
Chief Commercial Officer
Mitra RxDx
339.999.2306
pcassidy@mitrabiotech.com 
12 Gill Street, Suite 3150
Woburn, MA 01801
www.mitrabiotech.com

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/mitra-rxdx-announces-40-million-financing-round-300679739.html

SOURCE Mitra RxDx

Copyright 2018 PR Newswire

Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V:us D:20180920 18:58:22